# Hanlim Pharm. Co., Ltd. clinical trials: 50 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 50 trials with Hanlim Pharm. Co., Ltd. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Hanlim Pharm. Co., Ltd.: 50 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hanlim-pharm-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 50
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 50, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 20, 2026 | NCT07598968 | Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of HL1113-R1 and HL1113-R2 in Healthy Adult Volunteers | Hanlim Pharm. Co., Ltd. | Phase 1 | Completed | Hypertension, Diabete Type 2 | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598968) |
| May 6, 2026 | NCT07568652 | Clinical Trial to Evaluate the Pharmacokinetics and Safety Between the Single Administration of HL1113 and the Concomitant Administration... | Hanlim Pharm. Co., Ltd. | Phase 1 | Completed | Hypertension, Diabete Type 2 | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07568652) |
| April 27, 2026 | NCT07552389 | Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in... | Hanlim Pharm. Co., Ltd. | Phase 3 | Recruiting | Hypertension, Diabete Type 2 | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07552389) |
| October 15, 2024 | NCT06642987 | Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects. | Hanlim Pharm. Co., Ltd. | Phase 1 | Completed | Gastric Ulcer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06642987) |
| June 26, 2024 | NCT06475872 | Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" in... | Hanlim Pharm. Co., Ltd. | Phase 1 | Completed | Primary Hypercholesterolemia, Combined Hyperlipidemia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06475872) |
| May 30, 2024 | NCT06434792 | Study to Evaluate Efficacy and Safety of Bronpass Tab. in Patients With Chronic Obstructive Pulmonary Disease | Hanlim Pharm. Co., Ltd. | Phase 2 | Unknown | Chronic Obstructive Pulmonary Disease | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06434792) |
| February 7, 2024 | NCT06246331 | Evaluation of the Clinical Efficacy and Safety of BriTurn Injection or BrisTurn Prefilled Injection | Hanlim Pharm. Co., Ltd. | Observational | Unknown | Reversal of Neuromuscular Blockade | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06246331) |
| January 22, 2024 | NCT06214832 | An Observation Study on the Identification of Prescription Patterns of Lodient Tab(Telmisartan/S-amlodipine) | Hanlim Pharm. Co., Ltd. | Observational | Unknown | Hypertension | 4,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06214832) |
| January 12, 2024 | NCT06204380 | An Observational Study on the Identification of Prescription Patterns of STAFEN Cap | Hanlim Pharm. Co., Ltd. | Observational | Unknown | Mixed Dyslipidemia | 4,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06204380) |
| January 5, 2024 | NCT06191614 | DEXINEURO® Tab on Blood Glucose Reduction in Patients With Type 2 Diabetes Accompanied by Diabetic Peripheral Neuropathy | Hanlim Pharm. Co., Ltd. | Observational | Completed | Diabetic Peripheral Neuropathy | 528 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06191614) |
| January 3, 2024 | NCT06188234 | The Prescription Patterns and Clinical Efficacy of Tenero Tab/Tenero M SR Tab | Hanlim Pharm. Co., Ltd. | Observational | Unknown | Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06188234) |
| December 15, 2023 | NCT06172530 | Observational Study on the Improvement of Dry Eye Syndrome, Treatment Satisfaction, and Intraocular Tolerance With Diquasol Eye Drops | Hanlim Pharm. Co., Ltd. | Observational | Unknown | Dry Eye Syndrome | 2,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06172530) |
| November 14, 2023 | NCT06130124 | S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement | Hanlim Pharm. Co., Ltd. | Observational | Unknown | Essential Hypertension | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06130124) |
| May 3, 2022 | NCT05358080 | Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy | Hanlim Pharm. Co., Ltd. | Phase 4 | Unknown | Non Proliferative Diabetic Retinopathy | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05358080) |
| May 11, 2021 | NCT04882228 | Phase 4 Study to Evaluate Efficacy and Safety of Entelon Tab.150mg in Patients With Chronic Venous Disease(CVD) | Hanlim Pharm. Co., Ltd. | Phase 4 | Unknown | Chronic Venous Disease | 278 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04882228) |
| December 16, 2020 | NCT04667624 | Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers | Hanlim Pharm. Co., Ltd. | Phase 1 | Completed | Hypertension | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04667624) |
| December 9, 2020 | NCT04659070 | To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and... | Hanlim Pharm. Co., Ltd. | Phase 3 | Unknown | Primary Hypercholesterolemia, Hypertension | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04659070) |
| November 20, 2020 | NCT04638426 | Phase 2a Clinical Trial of HL237 for Rheumatoid Arthritis | Hanlim Pharm. Co., Ltd. | Phase 2 | Unknown | Rheumatoid Arthritis | 196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04638426) |
| November 18, 2020 | NCT04633733 | The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus | Hanlim Pharm. Co., Ltd. | Phase 1 | Unknown | Healthy Male Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04633733) |
| November 17, 2020 | NCT04632342 | Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients | Hanlim Pharm. Co., Ltd. | Phase 2 | Unknown | Radiation Pneumonitis, Lung Cancer | 87 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04632342) |
| October 28, 2020 | NCT04606329 | To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3) | Hanlim Pharm. Co., Ltd. | Phase 3 | Completed | Breast Diseases | 109 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04606329) |
| October 3, 2019 | NCT04114461 | Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers | Hanlim Pharm. Co., Ltd. | Phase 1 | Completed | Healthy Volunteers | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04114461) |
| April 1, 2019 | NCT03896594 | A Multiple Dose of HL237 in Healthy Male Subject | Hanlim Pharm. Co., Ltd. | Phase 1 | Unknown | Rheumatoid Arthritis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03896594) |
| November 16, 2018 | NCT03743259 | To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions | Hanlim Pharm. Co., Ltd. | Phase 2 | Completed | Breast Diseases | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03743259) |
| August 31, 2018 | NCT03655210 | To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients | Hanlim Pharm. Co., Ltd. | Phase 3 | Completed | Perennial Allergic Rhinitis | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03655210) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 20 |
| Phase 2 | 6 |
| Phase 3 | 13 |
| Phase 4 | 4 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 35 |
| Unknown | 14 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 7 |
| Diabetes Mellitus, Type 2 | 4 |
| Rhinitis, Allergic, Perennial | 4 |
| Dry Eye Syndromes | 3 |
| Arthritis, Rheumatoid | 3 |
| Osteoporosis | 3 |
| Bronchitis | 3 |
| Breast Diseases | 2 |
| Radiation Pneumonitis | 1 |
| Lung Neoplasms | 1 |
| Stomach Ulcer | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Pruritus | 1 |
| Osteoarthritis, Knee | 1 |
| Essential Hypertension | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Mexican restaurants in the United States](https://specstream.ai/data/businesses/mexican-restaurants/united-states)
- [Appliance manufacturers in the United States](https://specstream.ai/data/businesses/appliance-manufacturers/united-states)
- [Home automation companies in the United States](https://specstream.ai/data/businesses/home-automation-companies/united-states)
- [Surgery centers in the United States](https://specstream.ai/data/businesses/surgery-centers/united-states)
- [Door suppliers in the United States](https://specstream.ai/data/businesses/door-suppliers/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
